28494337|t|Quantification of apigenin trimethyl ether in rat plasma by liquid chromatography-tandem mass spectrometry: Application to a pre-clinical pharmacokinetic study
28494337|a|Apigenin trimethyl ether (5,7,4'-trimethoxyflavone, ATE) is a naturally occurring polymethoxyflavone with a wide range of health-promoting activities. In this study, a sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of ATE in rat plasma. Protein precipitation was applied as plasma clean-up procedure; the electrospray ionization was operated in its positive ion mode while ATE and formononetin (internal standard) were measured by multiple reactions monitoring (ATE: m/z 313.1→298.1; formononetin: 269.2→213.3). This LC-MS/MS method displayed good selectivity, sensitivity (lower limit of quantification =2.5ng/ml), accuracy (both intra- and inter-day analytical recovery within 100±10%) and precision (both intra- and inter-day RSD <10%). The matrix effect was found to be insignificant. The pharmacokinetic profiles of ATE were subsequently examined in Sprague-Dawley rats after single oral administration (10mg/kg). When given in an aqueous suspension, ATE was slowly absorbed with quite low plasma exposure (AUC). Fasting further attenuated its oral absorption and led to ∼70% drops in average maximal plasma concentration (Cmax) and AUC. When dosed in a solution formulated with 2-hydroxypropyl-β-cyclodextrin, the oral absorption of ATE was substantially improved with ∼500% increases in average Cmax and AUC. Clearly, aqueous solubility has been identified as a barrier to the oral absorption of ATE. The information obtained from this study will facilitate further medicinal exploration on ATE.
28494337	0	14	Quantification	T081	C1709793
28494337	18	42	apigenin trimethyl ether	T109,T121	C0533187
28494337	46	49	rat	T015	C0034721
28494337	50	56	plasma	T031	C0032105
28494337	60	106	liquid chromatography-tandem mass spectrometry	T059	C4049918
28494337	125	137	pre-clinical	T080	C1709630
28494337	138	159	pharmacokinetic study	T062	C0201734
28494337	160	184	Apigenin trimethyl ether	T109,T121	C0533187
28494337	186	210	5,7,4'-trimethoxyflavone	T109,T121	C0533187
28494337	212	215	ATE	T109,T121	C0533187
28494337	222	231	naturally	T169	C0205296
28494337	232	241	occurring	T079	C2745955
28494337	242	260	polymethoxyflavone	T109	C0016219
28494337	282	309	health-promoting activities	T033	C0517496
28494337	319	324	study	T062	C2603343
28494337	328	337	sensitive	T169	C0332324
28494337	338	384	liquid chromatography-tandem mass spectrometry	T059	C4049918
28494337	386	394	LC-MS/MS	T059	C4049918
28494337	396	402	method	T170	C0025663
28494337	407	416	developed	T169	C1527148
28494337	421	430	validated	T062	C1519941
28494337	439	453	quantification	T081	C1709793
28494337	457	460	ATE	T109,T121	C0533187
28494337	464	467	rat	T015	C0034721
28494337	468	474	plasma	T031	C0032105
28494337	476	497	Protein precipitation	T059	C3815102
28494337	502	509	applied	T169	C4048755
28494337	513	519	plasma	T031	C0032105
28494337	520	528	clean-up	T033	C3841937
28494337	529	538	procedure	T169	C2700391
28494337	544	567	electrospray ionization	T059	C1516801
28494337	588	605	positive ion mode	T169	C1513371
28494337	612	615	ATE	T109,T121	C0533187
28494337	620	632	formononetin	T109,T123	C0060656
28494337	634	651	internal standard	T081	C0034925
28494337	658	666	measured	T080	C0444706
28494337	670	699	multiple reactions monitoring	T170	C0025663
28494337	701	704	ATE	T109,T121	C0533187
28494337	723	735	formononetin	T109,T123	C0060656
28494337	756	771	LC-MS/MS method	T059	C4049918
28494337	782	786	good	T080	C0205170
28494337	787	811	selectivity, sensitivity	T081	C0036668
28494337	828	842	quantification	T081	C1709793
28494337	855	863	accuracy	T080	C0443131
28494337	870	876	intra-	T081	C0392762
28494337	881	910	inter-day analytical recovery	T081	C0392762
28494337	931	940	precision	T080	C1706245
28494337	947	953	intra-	T081	C0392762
28494337	958	971	inter-day RSD	T081	C0392762
28494337	983	996	matrix effect	T080	C1280500
28494337	1013	1026	insignificant	T080	C0205556
28494337	1032	1056	pharmacokinetic profiles	T169	C0031328
28494337	1060	1063	ATE	T109,T121	C0533187
28494337	1082	1090	examined	T033	C0332128
28494337	1094	1113	Sprague-Dawley rats	T015	C0034715
28494337	1127	1146	oral administration	T061	C0001563
28494337	1175	1193	aqueous suspension	T122	C0038960
28494337	1195	1198	ATE	T109,T121	C0533187
28494337	1210	1218	absorbed	T067	C1522240
28494337	1234	1240	plasma	T031	C0032105
28494337	1241	1249	exposure	T080	C0332157
28494337	1251	1254	AUC	T081	C0376690
28494337	1273	1283	attenuated	T052	C0599946
28494337	1288	1292	oral	T082	C0442027
28494337	1293	1303	absorption	T070	C0000854
28494337	1337	1344	maximal	T080	C0205289
28494337	1345	1365	plasma concentration	T081	C0683150
28494337	1367	1371	Cmax	T081	C0683150
28494337	1377	1380	AUC	T081	C0376690
28494337	1387	1392	dosed	T081	C0178602
28494337	1398	1406	solution	T167	C0037633
28494337	1407	1417	formulated	T062	C0524527
28494337	1423	1453	2-hydroxypropyl-β-cyclodextrin	T109,T121	C0046237
28494337	1459	1463	oral	T082	C0442027
28494337	1464	1474	absorption	T070	C0000854
28494337	1478	1481	ATE	T109,T121	C0533187
28494337	1486	1508	substantially improved	T033	C0184511
28494337	1520	1529	increases	T169	C0442805
28494337	1541	1545	Cmax	T081	C0683150
28494337	1550	1553	AUC	T081	C0376690
28494337	1564	1582	aqueous solubility	T081	C0597682
28494337	1608	1615	barrier	T033	C1704513
28494337	1623	1627	oral	T082	C0442027
28494337	1628	1638	absorption	T070	C0000854
28494337	1642	1645	ATE	T109,T121	C0533187
28494337	1651	1662	information	T078	C1533716
28494337	1682	1687	study	T062	C2603343
28494337	1712	1721	medicinal	T121	C0013227
28494337	1722	1733	exploration	T170	C3494260
28494337	1737	1740	ATE	T109,T121	C0533187